Candel Therapeutics (CADL) Equity Average (2021 - 2023)
Historic Equity Average for Candel Therapeutics (CADL) over the last 3 years, with Q3 2023 value amounting to $26.9 million.
- Candel Therapeutics' Equity Average fell 5205.57% to $26.9 million in Q3 2023 from the same period last year, while for Sep 2023 it was $26.9 million, marking a year-over-year decrease of 5205.57%. This contributed to the annual value of $55.9 million for FY2022, which is 17566.48% up from last year.
- Candel Therapeutics' Equity Average amounted to $26.9 million in Q3 2023, which was down 5205.57% from $35.2 million recorded in Q2 2023.
- Candel Therapeutics' 5-year Equity Average high stood at $63.9 million for Q1 2022, and its period low was $9.9 million during Q3 2021.
- For the 3-year period, Candel Therapeutics' Equity Average averaged around $45.7 million, with its median value being $49.9 million (2022).
- As far as peak fluctuations go, Candel Therapeutics' Equity Average surged by 46631.84% in 2022, and later tumbled by 5205.57% in 2023.
- Over the past 3 years, Candel Therapeutics' Equity Average (Quarter) stood at $63.6 million in 2021, then dropped by 21.46% to $49.9 million in 2022, then plummeted by 46.12% to $26.9 million in 2023.
- Its Equity Average was $26.9 million in Q3 2023, compared to $35.2 million in Q2 2023 and $43.7 million in Q1 2023.